Novel katG mutations causing isoniazid resistance in clinical M. Tuberculosis isolates

Emerging Microbes and Infections

Volumn 4, Issue 7, 2015, Pages e42-

  Torres, Jessica N ^a   Paul, Lynthia V ^b   Rodwell, Timothy C ^c   Victor, Thomas C ^b   Amallraja, Anu M ^a   Elghraoui, Afif ^a   Goodmanson, Amy P ^a   Ramirez Busby, Sarah M ^a   Chawla, Ashu ^a   Zadorozhny, Victoria ^a   Streicher, Elizabeth M ^b   Sirgel, Frederick A ^b   Catanzaro, Donald ^d   Rodrigues, Camilla ^e   Gler, Maria Tarcela ^f   Crudu, Valeru ^g   Catanzaro, Antonino ^c   Valafar, Faramarz ^a  

^a SAN DIEGO STATE UNIVERSITY   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF ARKANSAS   (United States)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f Tropical Disease Foundation Inc   (Philippines)

^g Microbiology and Morphology Laboratory   (Moldova)

Author keywords

Isoniazid drug resistance; KatG; MDR TB; Novel mutation; Pyrosequencing; Sanger sequencing; Tuberculosis; Whole genome sequencing

Indexed keywords

ISONIAZID; KATG PROTEIN; BACTERIAL PROTEIN; CATALASE; INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; INDIA; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PHILIPPINES; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SOUTH AFRICA; DRUG EFFECTS; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CATALASE; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; TUBERCULOSIS;

EID: 84940375601     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2015.42     Document Type: Article

References (68)

1. World Health Organization. Global Tuberculosis Report 2014. Geneva: WHO, 2014. Available at http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf (accessed 1 November 2014).
2. World Health Organization. Global Tuberculosis Report 2013. Geneva: WHO, 2013. Available at http://www.who.int/tb/publications/global-report/en/(accessed 3 July 2013).
3. Boehme CC, Nabeta P, Hillemann D et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363: 1005-1015.
4. Ferro BE, García PK, Nieto LM, van Soolingen D. Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. J Clin Microbiol 2013; 51: 2220-2224.
5. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 2011; 53: 369-372.
6. Varahram M, Nasiri MJ, Farnia P, Mozafari M, Velayati AA. A retrospective analysis of isoniazid-monoresistant tuberculosis: Among Iranian pulmonary tuberculosis patients. Open Microbiol J 2013; 8: 1-5.
7. Gagneux S, Burgos M V, DeRiemer K et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis. PLoS Pathog 2006; 2: e61.
8. Yu S, Girotto S, Lee C, Magliozzo RS. Reduced affinity for Isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance. J Biol Chem 2003; 278: 14769-14775.
9. Pym AS, Saint-Joanis B, Cole ST. Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 2002; 70: 4955-4960.
10. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazidresistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-1531.
11. Larsen MH, Vilchèze C, Kremer L et al. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol Microbiol 2002; 46: 453-466.
12. Rodwell TC, Valafar F, Douglas J et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014; 52: 781-789.
13. Wei C-J, Lei B, Musser JM, Tu S-C. Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother 2003; 47: 670-675.
14. Siqueira HR, Freitas FA, Oliveira DN, Barreto AM, Dalcolmo MP, Albano RM. Isoniazid-resistant Mycobacterium tuberculosis strains arising from mutations in two different regions of the katG gene. J Bras Pneumol 2009; 35: 773-779.
15. Ramaswamy SV, Reich R, Dou SJ et al. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 1241-1250.
16. Ando H, Miyoshi-Akiyama T, Watanabe S, Kirikae T. A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis. Mol Microbiol 2014; 91: 538-547.
17. Hillery N, Groessl EJ, Trollip A et al. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis. Trials 2014; 15: 434.
18. Canetti G, Fox W, Khomenko A et al. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
19. Garfein RS, Catanzaro DG, Rodwell TC et al. Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium Tuberculosis isolates. Int J Tuberc Lung Dis 2015; 19: 420-427.
20. Kamerbeek J, Schouls L, Kolk A et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J ClinMicrobiol 1997; 35: 907-914.
21. Cowan LS, Diem L, Monson T et al. Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. J Clin Microbiol 2005; 43: 688-695.
22. Mazars E, Lesjean S, Banuls AL et al. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Natl Acad Sci U S A 2001; 98: 1901-1906.
23. Shabbeer A, Cowan LS, Ozcaglar C et al. TB-Lineage: An online tool for classification and analysis of strains of Mycobacterium tuberculosis complex. Infect Genet Evol 2012; 12: 789-797.
24. Aminian M, Couvin D, Shabbeer A et al. Predicting Mycobacterium tuberculosis complex clades using knowledge-based Bayesian networks. Biomed Res Int 2014; 2014: 398484.
25. Ajbani K, Lin SY, Rodrigues C et al. Evaluation of Pyrosequencing for Detecting Extensively Drug-resistant Tuberculosis (XDR-TB) in clinical isolates from four highburden countries. Antimicrob Agents Chemother 2015; 59: 414-420.
26. Van Helden PD, Victor TC, Warren RM, van Helden EG. Isolation of DNA from Mycobacterium tubercolosis. Methods Mol Med 2001; 54: 19-30.
27. QIAGEN. QIAGEN Genomic DNA Handbook 04/2012. Hilden: QIAGEN Technical Support, 2012.
28. Van der Auwera GA, Carneiro MO, Hartl C et al. From FastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatis 2013; 11: 11101-111033.
29. McKenna A, Hanna M, Banks E et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
30. DePristo MA, Banks E, Poplin R et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
31. Li H, Handsaker B, Wysoker A et al. The Sequence Alignment/Map format and SAM tools. Bioinformatics 2009; 25: 2078-2079.
32. Barnett DW, Garrison EK, Quinlan AR, Strömberg MP, Marth GT. BamTools: A C11 API and toolkit for analyzing and managing BAM files. Bioinformatics 2011; 27: 1691-1692.
33. Koboldt DC, Chen K, Wylie T et al. VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 2009; 25: 2283-2285.
34. Koboldt DC, Zhang Q, Larson DE et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
35. Lin SY, Rodwell TC, Victor TC et al. Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 2014; 52: 475-482.
36. Borrell S, Teo Y, Giardina F et al. Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis. Evol Med public Heal 2013; 2013: 65-74.
37. Koch A, Mizrahi V, Warner DF. The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin? Emerg Microbes Infect 2014; 3: e17.
38. Xu X, Vilchèze C, Av-Gay Y, Gómez-Velasco A, Jacobs WR. Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2011; 55: 3133-3139.
39. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992; 358: 591-593.
40. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson DI, Böttger EC. Directed mutagenesis of Mycobacterium smegmatis 16S rRNA to reconstruct the in-vivo evolution of aminoglycoside resistance in Mycobacterium tuberculosis. Mol Microbiol 2010; 77: 830-840.
41. Parish T, Roberts G, Laval F, Schaeffer M, Daffé M, Duncan K. Functional complementation of the essential gene fabG1 of Mycobacterium tuberculosis by Mycobacterium smegmatis fabG but not Escherichia coli fabG. J Bacteriol 2007; 189: 3721-3728.
42. Burian J, Yim G, Hsing M et al. The mycobacterial antibiotic resistance determinant WhiB7 acts as a transcriptional activator by binding the primary sigma factor SigA (RpoV). Nucleic Acids Res 2013; 41: 10062-10076.
43. Karunakaran P, Davies J. Genetic antagonism and hypermutability in Mycobacterium smegmatis. J Bacteriol 2000; 182: 3331-3335.
44. Johnson R, Streicher EM, Louw GE, Warren RM, van Helden PD, Victor TC. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8: 97-111.
45. Parish T, Stoker NG. Use of flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology 2000; 146: 1969-1975.
46. Thermo Scientific. Phusion Polymerase. Waltham, MA: Thermo Scientific, 2014. Available at http://www.thermoscientificbio.com/pcr-enzymes-master-mixes-andreagents/phusion-high-fidelity-dna-polymerase/(accessed 1 May 2014).
47. Edelheit O, Hanukoglu A, Hanukoglu I. Simple and efficient site-directed mutagenesis using two single-primer reactions in parallel to generate mutants for protein structurefunction studies. BMC Biotechnol 2009; 9: 61.
48. Chan RC, Hui M, Chan EWC et al. Genetic and phenotypic characterization of drugresistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother 2007; 59: 866-873.
49. Heym B, Alzari PM, Honore N, Cole ST. Missense mutations in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol 1995; 15: 235-245.
50. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43: 3699-3703.
51. Choi JH, Lee KW, Kang HR et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010; 137: 393-400.
52. Jagielski T, Grzeszczuk M, Kamiń ski M et al. Identification and analysis of mutations in the katG gene in multidrug-resistant Mycobacterium tuberculosis clinical isolates. Pneumonol Alergol Pol 2013; 81: 298-307.
53. Zaker Bostanabad S, Titov LP, Slizen VV, Taghikhani M, Bahrmand A. katG mutations in isoniazid-resistant strains of Mycobacterium tuberculosis isolates from Belarusian patients. Tuberk Toraks 2007; 55: 231-237.
54. Rouse DA, Li Z, Bai GH, Morris SL. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2472-2477.
55. Vilchèze C, Wang F, Arai M et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12: 1027-1029.
56. Pretorius GS, van Helden PD, Sirgel F, Eisenach KD, Victor TC. Mutations in katG gene sequences in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis are rare. Antimicrob Agents Chemother 1995; 39: 2276-2281.
57. Fenner L, Egger M, Bodmer T et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3047-3053.
58. Cockerill FR 3rd, Uhl JR, Temesgen Z et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis 1995; 171: 240-245.
59. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998; 79: 3-29.
60. Sreevatsan S, Pan X, Stockbauer KE et al. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997; 94: 9869-9874.
61. Tukvadze N, Kempker RR, Kalandadze I et al. Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis. PLoS One 2012; 7: e31563.
62. García-Sierra N, Lacoma A, Prat C et al. Pyrosequencing for rapid molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2011; 49: 3683-3686.
63. Piatek AS, Telenti A, Murray MR et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000; 44: 103-110.
64. Ramasubban G, Therese KL, Lakshmipathy D, Sridhar R, Meenakshi N, Madhavan HN. Detection of novel and reported mutations in the rpoB, katG and inhA genes in multidrug-resistant tuberculosis isolates: A hospital-based study. J Glob Antimicrob Resist 2014; 3: 1-4.
65. Ando H, Kondo Y, Suetake T et al. Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 1793-1799.
66. Syah YM, Retnoningrum DS, Noer AS, Shigeoka S, Natalia D. Novel mutations in katG gene of a clinical isolate of isoniazid-resistant Mycobacterium tuberculosis. Biologia (Bratisl) 2012; 67: 41-47.
67. Lee AS, Lim IH, Tang LL, Telenti A, Wong SY. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob Agents Chemother 1999; 43: 2087-2089.
68. Daniel J, Oh TJ, Lee CM, Kolattukudy PE. AccD6, a member of the Fas II locus, is a functional carboxyltransferase subunit of the acyl-coenzyme A carboxylase in Mycobacterium tuberculosis. J Bacteriol 2007; 189: 911-917.